BioVie (Nasdaq: BIVI): Advancing Breakthrough Therapies for Alzheimer’s, Parkinson’s & Liver Disease
Jun. 11, 2025
BioVie is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate bezisterim inhibits inflammatory activation that leads to neuroinflammation, and insulin resistance believed to be drivers of Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). Bezisterim is also being developed to address Long COVID, with a Phase 2 trial expected to commence in early 2025. In liver disease, the Company’s Orphan drug candidate BIV201 (continuous infusion terlipressin), with U.S. FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis.
BioVie is a client of RedChip. Visit www.redchip.com/stocks/bivi to learn more.
